Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,521 questions in 132 reviews · Hepato-Biliary
current versionsNo studies 303 · 19.9%Ungraded 39 · 2.6%Very low 876 · 57.6%Low 216 · 14.2%Moderate 65 · 4.3%High 22 · 1.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Microwave coagulation vs conventional surgery Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Microwave coagulation vs conventional surgery Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs radiofrequency ablation All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | RR 0.62 [0.26, 1.47] | 1 study · 50 participants | Very low |
Microwave coagulation vs radiofrequency ablation Time to mortality (overall survival) · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | HR 0.63 [0.23, 1.73] | 1 study · 50 participants | Very low |
Microwave coagulation vs radiofrequency ablation Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs radiofrequency ablation Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | RR 0.19 [0.01, 3.67] | 1 study · 50 participants | Very low |
Microwave coagulation vs radiofrequency ablation Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Time to mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs radiofrequency ablation Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | 1 study · 50 participants | Ungraded |
Microwave coagulation vs radiofrequency ablation Recurrence of liver metastases local progression · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | RR 0.19 [0.01, 3.67] | 1 study · 50 participants | Very low |
Microwave coagulation vs radiofrequency ablation Recurrence of liver metastases distant recurrence · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | RR 1.03 [0.5, 2.08] | 1 study · 50 participants | Very low |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | 1 study · 50 participants | Very low |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | 1 study · 40 participants | Ungraded |
Microwave coagulation vs conventional surgery Time to mortality (overall survival) · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | HR 0.91 [0.39, 2.15] | 1 study · 30 participants | Very low |
Transjugular intrahepatic portosystemic shunts vs conventional treatment All‐cause mortality · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | RR 0.88 [0.55, 1.38] | 2 studies · 130 participants | Very low |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Morbidity due to any cause · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | RR 0.95 [0.77, 1.18] | 2 studies · 130 participants | Low |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Serious adverse events · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | RR 1.6 [0.1, 24.59] | 2 studies · 130 participants | Very low |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Health‐related quality of life · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Participants who did not receive a liver transplant · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | RR 1.03 [0.93, 1.14] | 2 studies · 130 participants | Very low |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Participants without improvement in kidney function · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | RR 0.53 [0.27, 1.02] | 1 study · 70 participants | Low |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Length of hospitalisation measured in days · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Intervention NR All‐cause mortality · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs moderate NMB All‐cause mortality short‐term · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | Peto OR 7.22 [0.45, 115.43] | 12 studies · 1390 participants | Very low |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs no NMB Serious adverse events (SAEs) start of surgery until 8 hours after surgery · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | 1 study · 25 participants | Very low |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs moderate NMB Health‐related quality of life · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | 5 studies · 440 participants | Moderate |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs moderate NMB Serious adverse events (SAEs) start of surgery until 8 hours after surgery · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | Peto OR 0.95 [0.59, 1.52] | 21 studies · 2231 participants | Very low |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs moderate NMB Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | Peto OR 0.9 [0.56, 1.42] | 16 studies · 1764 participants | Very low |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs shallow NMB All‐cause mortality ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs shallow NMB Health‐related quality of life ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs shallow NMB Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | RR 1.66 [0.5, 5.57] | 2 studies · 158 participants | Very low |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs no NMB All‐cause mortality start of surgery ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs no NMB Health‐related quality of life ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care alone Overall survival (absolute effect size estimates based on survival rate at 20 months) (censored observation) · participants with advanced hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | HR 1.19 [0.78, 1.82] | 1 study · 129 participants | Very low |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Adverse events considered non‐serious (number of participants) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 20.13 [1.25, 324] | 1 study · 45 participants | Very low |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation All‐cause mortality · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 0.4 [0.22, 0.73] | 1 study · 86 participants | Low |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Overall survival Censored · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 3.06 [0.16, 60.47] | 1 study · 48 participants | Very low |